American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
about
Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cellsTamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionAssociation between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCAmerican Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsEarly-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsPotential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancerDiverse roles of SIRT1 in cancer biology and lipid metabolismMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelinePharmacogenomics of breast cancer therapy: an updateImpact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifenClinical utilities of aromatase inhibitors in breast cancerOrphan nuclear receptor HNF4G promotes bladder cancer growth and invasion through the regulation of the hyaluronan synthase 2 geneThe global burden of women's cancers: a grand challenge in global health.Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoCYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive EarlyEfficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic reviewPreparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies."Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice.The Long and Short of Tamoxifen Therapy: A Review of the ATLAS TrialGenotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review.Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report.Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective studyAmerican society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
P2860
Q24319134-9848CBB3-948E-4048-84D6-E45E68FB9A02Q24605762-92635186-14C6-4D55-A6C1-27A448F3DA8DQ24632347-FAF3A9F6-FFB3-48CA-95D4-7CA67C77E0FDQ26747276-88424D44-FB1C-4DDF-BCC8-92BDC67F4AEBQ26773986-817B67AF-0D22-4EF7-B94E-3144E07ADAC3Q26782449-C364872A-8DF8-42C2-BE73-D6BE88D40DC9Q26782584-D7359466-140F-488E-A38B-CAD7F9D9794AQ26824762-9E3D7D66-3923-48EC-A61B-8DB68411F778Q26863685-66F8E4CE-7AC2-4318-B92D-8328D1152A68Q26997827-AA1974D9-01D3-4CDE-B072-CEDAA4137C9FQ27001260-19BEE2D6-3B76-46C1-ADF2-D5270981A26FQ27002430-CE6FBE3B-E450-47BE-AC40-5F09D3FC4E43Q27006783-7501DDB6-7EDB-46BC-9436-1C77B1620EA0Q27026180-6A656A0C-7BE1-45DA-9E2D-9F1DC4093768Q28081168-1D63C3D6-10C4-4457-A5C5-AE44D9FA8594Q29347539-4678E316-7DBF-4943-8486-4FD8FFF2B545Q30241791-1D11345A-646B-4792-8A23-67476A1852A9Q30275126-7F7DE0B6-7B32-44DC-8516-3A9A9C3AACABQ30400967-ED412344-5AC7-4CCB-A55E-9A9AAD2EE308Q30732631-1F8640E4-60B4-4A71-930B-CD95A16A6F2BQ33441090-490E035E-A9CC-42F3-9EC2-718C5E33385CQ33559178-06581E73-7B08-41E4-A00E-258C6C5A7E11Q33562869-4B05C213-E33F-4D20-BB26-BC398FA1B876Q33655236-D07BBDD1-F6D9-4C08-AF8C-0882C0C55D0BQ33658005-7183F7F2-1DA9-4167-A8FA-7FABB356DF29Q33698446-1904CAFF-F7DF-470A-BDBF-7984189C51D2Q33729085-6B099861-3AE0-4CE1-ACD5-442670492397Q33736780-C8CCC924-D5C0-4A61-88A8-1704DD54212BQ33756757-5C75153B-7ADB-48F7-93B3-EBA6C82AE9FBQ33777302-D2A0195D-8378-4A26-83B2-7130439B32A6Q33821112-5D9178EB-0E4B-45DC-890B-C32E6BCD6A3CQ33886176-E4F72021-F783-413F-8906-8EABA9DFC450Q33901118-145BD563-3BFA-4DAE-886B-E5101219CA0AQ33989364-8FBB04AF-E94E-4AE8-BDB5-95BA5F19862FQ34007066-CF221E9C-EB29-41DC-9D6E-2305F6E59CD2Q34020925-AD83C0FE-9CC2-4E29-9A47-83A94DD9AE08Q34070054-DEBCA916-8F83-43ED-8A4E-B65376D8233EQ34113564-EAEDBDCC-C96B-40A0-BD79-41AF33971B4AQ34114894-C9BDD5E8-D870-4A48-AA0E-CD7314847A84Q34134780-424EDCD3-AF1D-4C26-8647-F313CCF92A4F
P2860
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
American Society of Clinical O ...... ceptor-positive breast cancer.
@ast
American Society of Clinical O ...... ceptor-positive breast cancer.
@en
type
label
American Society of Clinical O ...... ceptor-positive breast cancer.
@ast
American Society of Clinical O ...... ceptor-positive breast cancer.
@en
prefLabel
American Society of Clinical O ...... ceptor-positive breast cancer.
@ast
American Society of Clinical O ...... ceptor-positive breast cancer.
@en
P2093
P2860
P50
P356
P1476
American Society of Clinical O ...... ceptor-positive breast cancer.
@en
P2093
Alexander J Solky
Ann Alexis Prestrud
Clifford A Hudis
Diana Rowden
Eleftherios P Mamounas
Eric P Winer
Harold J Burstein
Holly Anderson
Jennifer J Griggs
Jennifer Malin
P2860
P304
P356
10.1200/JCO.2009.26.3756
P407
P577
2010-07-12T00:00:00Z